Clinical evaluation shows durable tumor remission and favorable overall survival in advanced melanoma, suggesting prolonged benefits from nivolumab.
Overall survival following nivolumab treatment in patients with advanced treatment-refractory melanoma compares favorably with that in literature studies of similar patient populations. Responses were durable and persisted after drug discontinuation. Long-term safety was acceptable. Ongoing randomized clinical trials will further assess the impact of nivolumab therapy on overall survival in patients with metastatic melanoma.
No takes yet. Share an insight, caveat, or question.
Topalian et al. (2014) studied this question.